- Apollo Endosurgery, Inc. (APEN) was already down 85% from its 2016 debut price when the pandemic cratered sales of its elective procedure-leveraged endoscopy devices.
- Short on cash, the company was forced to execute a substantially dilutive secondary offering in July 2020 at $1.25 a share.
- With a 3Q20 revenue rebound, a likely FDA clearance of its colonoscopy suture candidate imminent, and a one-day 77% analyst upgrade-induced rally, Apollo merited further investigation.
- A full investment analysis follows in the paragraphs below.
For further details see:
Assessing Apollo Endosurgery